Semen Yesylevskyy is a distinguished expert in molecular simulations and computational drug evaluation, currently serving as Co-founder and Chief Scientific Officer at RECEPTOR.AI since March 2021. In addition to this role, Semen holds research positions at Palacký University in Olomouc, the IOCB Prague, and the Institute of Physics of the National Academy of Sciences of Ukraine, focusing on membranotropic compounds, interaction of fusogenic agents with lipid membranes, and Molecular Dynamics simulations of lipid membranes, respectively. Semen's previous experience includes a Research Fellow position at Université de Franche-Comté, postdoctoral research at the University of Groningen, and an invited researcher role at The University of Queensland, contributing to various aspects of molecular modeling and simulations. Semen Yesylevskyy obtained a Master's degree in Physics from the National University of Kyiv-Mohyla Academy.
This person is not in any teams
This person is not in any offices
IOCB Prague - Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
1 followers
The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. Today, over 600 employees including 180 students in 45 research and service groups are involved in a broad spectra of disciplines, which results in more than 250 publications per year, including papers in the most cited prestigious journals such as Nature or Science. The Institute’s emphasis on interaction between chemistry and other sciences leads frequently to medicinal applications. An integral part of the mission of the Institute is, therefore, to transfer the scientific results into assets which help people to live better lives. Together with the research expertise, a system of technology transfer, IP management and commercialization have intensively been built-up. Through its subsidiary company IOCB TTO, the Institute helps scientists to transform ideas into patents and matches their research results with interests of commercial partners to bring novel ideas to human use or technology market.